Free Trial

Quest Diagnostics (DGX) Stock Price, News & Analysis

Quest Diagnostics logo
$179.26 -0.37 (-0.20%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Quest Diagnostics Stock (NYSE:DGX)

Key Stats

Today's Range
$178.07
$181.15
50-Day Range
$169.57
$182.06
52-Week Range
$136.30
$182.38
Volume
515,951 shs
Average Volume
991,806 shs
Market Capitalization
$20.01 billion
P/E Ratio
22.66
Dividend Yield
1.79%
Price Target
$185.73
Consensus Rating
Moderate Buy

Company Overview

Quest Diagnostics, founded through a series of corporate spin-offs and acquisitions in the mid-1990s, is a leading provider of diagnostic testing, information, and services. Headquartered in Secaucus, New Jersey, the company operates one of the largest clinical laboratory networks in the United States, supported by a comprehensive suite of laboratory information systems and logistics infrastructure. Quest Diagnostics serves healthcare providers, hospitals, employers, insurers and patients, enabling accurate and timely diagnosis and disease monitoring.

The company’s core offerings include routine and specialty laboratory tests spanning more than 3,000 tests and test combinations. These services encompass clinical chemistry, immunology, molecular diagnostics, genetic and genomic testing, and anatomic pathology. Quest Diagnostics also offers digital health and telehealth solutions, allowing physicians and patients to access test results, order services and manage chronic conditions through secure online platforms and mobile applications. The company has further expanded into wellness and occupational health services, delivering preventive screening and on-site testing programs for corporate and community clients.

Quest Diagnostics maintains a nationwide network of laboratories, patient service centers, and mobile collection sites, ensuring broad geographic coverage across all 50 states and select international markets. It partners with major hospital systems, healthcare networks and public health agencies to support population health management and large-scale testing initiatives. Internationally, Quest has established collaborations and joint ventures to extend its diagnostic capabilities into Europe, Latin America and Asia Pacific regions.

Under the leadership of Chairman and Chief Executive Officer Steve Rusckowski, Quest Diagnostics has pursued strategic acquisitions and investments in advanced testing technologies and digital platforms. The company continues to focus on innovative diagnostics solutions and expanding access to care, aiming to improve health outcomes through early detection and personalized medicine. With a commitment to quality, regulatory compliance and scientific rigor, Quest Diagnostics remains a cornerstone of the global healthcare ecosystem.

AI Generated. May Contain Errors.

Quest Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

DGX MarketRank™: 

Quest Diagnostics scored higher than 99% of companies evaluated by MarketBeat, and ranked 19th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Quest Diagnostics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Quest Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Quest Diagnostics are expected to grow by 8.14% in the coming year, from $9.70 to $10.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Quest Diagnostics is 22.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Quest Diagnostics is 22.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.45.

  • Price to Earnings Growth Ratio

    Quest Diagnostics has a PEG Ratio of 2.48. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Quest Diagnostics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Quest Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    3.28% of the float of Quest Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Quest Diagnostics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Quest Diagnostics has recently decreased by 4.71%, indicating that investor sentiment is improving.
  • Dividend Yield

    Quest Diagnostics pays a meaningful dividend of 1.80%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Quest Diagnostics has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Quest Diagnostics is 40.46%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 30.51% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

  • Read more about Quest Diagnostics' dividend.
  • Percentage of Shares Shorted

    3.28% of the float of Quest Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Quest Diagnostics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Quest Diagnostics has recently decreased by 4.71%, indicating that investor sentiment is improving.
  • News Sentiment

    Quest Diagnostics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Quest Diagnostics this week, compared to 16 articles on an average week.
  • Search Interest

    6 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,190,045.00 in company stock.

  • Percentage Held by Insiders

    Only 8.16% of the stock of Quest Diagnostics is held by insiders.

  • Percentage Held by Institutions

    88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Quest Diagnostics' insider trading history.
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock News Headlines

Quest Diagnostics Incorporated (DGX) - Yahoo Finance
DGX - Quest Diagnostics Inc Executives - Morningstar
Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
DGX Quest Diagnostics Incorporated - Seeking Alpha
See More Headlines

DGX Stock Analysis - Frequently Asked Questions

Quest Diagnostics' stock was trading at $150.86 at the beginning of 2025. Since then, DGX stock has increased by 18.9% and is now trading at $179.3620.
View the best growth stocks for 2025 here
.

Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Tuesday, April, 22nd. The medical research company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.06. The medical research company earned $2.65 billion during the quarter, compared to the consensus estimate of $2.63 billion. Quest Diagnostics had a trailing twelve-month return on equity of 15.11% and a net margin of 8.81%.
Read the conference call transcript
.

Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others.

Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO.

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

Record date for 4/21 Dividend
4/07/2025
Ex-Dividend for 4/21 Dividend
4/07/2025
Dividend Payable
4/21/2025
Last Earnings
4/22/2025
Today
7/01/2025
Record date for 7/21 Dividend
7/07/2025
Ex-Dividend for 7/21 Dividend
7/07/2025
Dividend Payable
7/21/2025
Next Earnings (Estimated)
7/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DGX
Employees
56,000
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$185.73
High Stock Price Target
$200.00
Low Stock Price Target
$170.00
Potential Upside/Downside
+3.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

Trailing P/E Ratio
22.70
Forward P/E Ratio
18.51
P/E Growth
2.48
Net Income
$871 million
Pretax Margin
11.67%

Debt

Sales & Book Value

Annual Sales
$9.87 billion
Cash Flow
$13.63 per share
Price / Cash Flow
13.17
Book Value
$61.38 per share
Price / Book
2.92

Miscellaneous

Free Float
102,526,000
Market Cap
$20.04 billion
Optionable
Optionable
Beta
0.49

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NYSE:DGX) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners